Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Castle Creek (Details) $ / shares in Units, $ in Thousands		1 Months Ended	12 Months Ended
	Sep. 17, 2025 USD ($)	Feb. 28, 2025 USD ($) $ / shares shares	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Agreements
Aggregate purchase price	$ 98,968
Long-term royalty and commercial payment receivables under the cost recovery method			$ 55,888	$ 55,936
Short-term royalty and commercial payment receivables under the cost recovery method			0	413
Payments of consideration under RPAs, AAAs and CPPAs			8,000	$ 53,000
Fair value of warrants			697
Royalty Financing Transaction | Castle Creek Biosciences, Inc
Agreements
Rights entity acquired as a percentage of specified percentage		6.70%
Percentage of domestic sales		8.75%
Percentage of worldwide sales		8.00%
Percentage of proceeds from potential PRV		20.00%
Number of warrants received | shares		10,464
Exercise price of warrants received (in dollars per share) | $ / shares		$ 215.03
Term of warrants received		10 years
Aggregate purchase price		$ 5,000
Long-term royalty and commercial payment receivables under the cost recovery method		4,400
Short-term royalty and commercial payment receivables under the cost recovery method			0
Allowance for credit losses			0
Fair value of warrants		$ 700	$ 700
Period between issuance and expiration		4 years 6 months
Royalty Financing Transaction | Castle Creek Biosciences, Inc | Volatility
Agreements
Derivative Asset, Measurement Input		120.6
Royalty Financing Transaction | Castle Creek Biosciences, Inc | Risk-free interest rate
Agreements
Derivative Asset, Measurement Input		3.69